Autoimmune hepatitis.

Area of Science:

• Pediatric Gastroenterology
• Hepatology
• Immunology

Background:

• Autoimmune hepatitis (AIH) is an inflammatory liver disease defined by autoantibodies and elevated immunoglobulin G, without a clear cause.
• Juvenile AIH presents as type 1 (smooth muscle/anti-nuclear antibody positive) or type 2 (liver kidney microsomal antibody positive), with a female predominance.
• AIH type 2 often presents earlier and more acutely, sometimes with immunoglobulin A deficiency, but long-term outcomes are similar between types.

Purpose of the Study:

• To review the current understanding of diagnosis, monitoring, and treatment of autoimmune hepatitis in children.
• To differentiate AIH from autoimmune sclerosing cholangitis in pediatric patients.
• To highlight the importance of timely immunosuppressive therapy to prevent disease progression.

Main Methods:

• Review of existing literature on pediatric autoimmune hepatitis and related conditions.
• Analysis of diagnostic criteria, including serological markers and histology.
• Evaluation of treatment strategies and their efficacy in managing AIH and autoimmune sclerosing cholangitis.

Main Results:

• Immunosuppressive therapy (steroids, azathioprine) induces remission in approximately 80% of AIH cases, though relapses are common.
• Long-term treatment is often necessary, with only 20% of AIH type 1 patients successfully discontinuing therapy.
• Autoimmune sclerosing cholangitis, prevalent in children, shares features with AIH type 1 but requires cholangiography for diagnosis; liver damage responds to immunosuppression, while bile duct issues may progress.

Conclusions:

• Prompt immunosuppressive treatment is vital for managing pediatric AIH and preventing cirrhosis.
• While effective, long-term management and monitoring are essential due to frequent relapses.
• Distinguishing AIH from autoimmune sclerosing cholangitis is critical for appropriate therapeutic approaches in children.